Stock ATRC ATRICURE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News AtriCure, Inc.

Equities

ATRC

US04963C2098

Market Closed - Nasdaq
Other stock markets
 21:00:00 15/05/2024 BST 		5-day change 1st Jan Change
22.12 USD +1.05% Intraday chart for AtriCure, Inc. +6.91% -38.02%
05-14 Transcript : AtriCure, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 10:15 AM
05-02 Needham Lowers AtriCure's PT to $40 From $46 Due to Peer Multiple Contraction, Keeps Buy Rating MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
AtriCure to Participate in the 2024 Leerink Partners Healthcare Crossroads Conference
BU
Transcript : AtriCure, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 10:15 AM
Needham Lowers AtriCure's PT to $40 From $46 Due to Peer Multiple Contraction, Keeps Buy Rating
MT
Earnings Flash (ATRC) ATRICURE Reports Q1 Revenue $108.9M, vs. Street Est of $106.9M
MT
AtriCure: Q1 Earnings Snapshot
AQ
Transcript : AtriCure, Inc., Q1 2024 Earnings Call, May 01, 2024
AtriCure Reports First Quarter 2024 Financial Results
BU
AtriCure, Inc. Provides Earnings Guidance for the Year 2024
CI
AtriCure, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
AtriCure to Participate in the 2024 Bank of America Securities Healthcare Conference
BU
Oppenheimer Upgrades AtriCure to Outperform, Price Target at $32
MT
AtriCure Announces Launch of the cryoSPHERE+ Probe for Post-Operative Pain Management
AQ
AtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative Pain Management
BU
AtriCure, Inc. Announces Launch of the CryoSPHERE®?+ Probe for Post-Operative Pain Management
CI
AtriCure to Announce First Quarter 2024 Financial Results
BU
AtriCure to Participate in the 23rd Annual Needham Virtual Healthcare Conference
BU
AtriCure Insider Sold Shares Worth $307,510, According to a Recent SEC Filing
MT
Atricure, Inc. Appoints Shlomi Nachman as Director, Member of Each of the Board?s Strategy Committee and Compliance, Quality and Risk Committee
CI
UBS Adjusts AtriCure Price Target to $58 From $57, Maintains Buy Rating
MT
Stifel Adjusts Price Target on AtriCure to $42 From $50, Maintains Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ATRC Stock
  4. News AtriCure, Inc.